Successful treatment of in-transit metastatic melanoma with combination intralesional T-VEC and topical imiquimod immunotherapy
Open Access
- 19 November 2024
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 12 (11) , e009581
Abstract
In-transit metastases of malignant melanoma pose a significant clinical challenge, particularly in patients with contraindications to systemic therapies. While surgical excision and systemic immunotherapies remain standard treatments, localized therapies such as intralesional talimogene laherparepvec (T-VEC) and topical imiquimod, which stimulate tumor-specific T-cell responses, have garnered increasing attention for their potential efficacy and tolerability. Although the individual efficacy of these therapies is well-documented, their combined use and their synergistic effects have not been well-documented. This case series reports on five patients with in-transit melanoma metastases treated with T-VEC and imiquimod at Northwestern Memorial Hospital from November 2018 to May 2023. Patients received a median of 13 (range 8–20) T-VEC injections over a median of 6 months (range 5–9), of which 4 of those months were with concurrent T-VEC and imiquimod cream. Four of the five patients achieved complete response (CR) by the end of the treatment course. One patient developed systemic progression during therapy, leading to early cessation of treatment. All patients with CR elected to continue topical imiquimod applications as maintenance following T-VEC for a median of 6 months (range 2–14 months). Only one of the four patients who achieved CR developed metastatic nodal disease 10 months after the last T-VEC injection. The three other patients are free of cutaneous and systemic disease 2–57 months after their last injection. All patients tolerated treatment well with zero patients discontinuing treatment due to side effects. These findings suggest that the combination of intralesional T-VEC and topical imiquimod can be an effective and safe treatment of in-transit metastases of malignant melanoma.Keywords
This publication has 8 references indexed in Scilit:
- Topical imiquimod and cryotherapy in combination with systemic immunotherapy in unresectable stage IIIC melanomaJAAD Case Reports, 2022
- In-transit metastatic cutaneous melanoma: current management and future directionsClinical & Experimental Metastasis, 2021
- Novel Treatment of In-Transit Metastatic Melanoma With Shave Excision, Electrodesiccation and Curettage, and Topical Imiquimod 5% Cream2021
- Successful Treatment of In-Transit Metastatic Melanoma in a Renal Transplant Patient With Combination T-VEC/Imiquimod ImmunotherapyJournal of Immunotherapy, 2020
- Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion SizeAnnals of Surgical Oncology, 2019
- Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimodMelanoma Research, 2016
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaJournal of Clinical Oncology, 2015
- The Risk of In-Transit Melanoma Metastasis Depends on Tumor Biology and Not the Surgical Approach to Regional Lymph NodesJournal of Clinical Oncology, 2005